Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Liraglutide Up For Approval In U.S. And Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

Novo Nordisk’s type 2 diabetes drug could face hurdles once longer-acting GLP-1s hit the market.

You may also be interested in...



Novo Nordisk, Emisphere Collaborate To Propel Oral GLP-1 Compounds In R&D

Emisphere carrier technology may be applied to other compounds as well.

Novo Nordisk, Emisphere Collaborate To Propel Oral GLP-1 Compounds In R&D

Emisphere carrier technology may be applied to other compounds as well.

Roche/Ipsen Plan 2010 Filing For Once-Weekly GLP-1 Analog

Phase III studies pitting once-weekly taspoglutide against Lilly's Byetta and Merck's Januvia commence in the second half.

Related Content

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel